Business
Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates
MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal
About this update from Xencor, Inc.
[{"type":"text","content":" MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--\nXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to study investigational treatments for patients with a variety of cancer types. The parties will collaborate to design and execute additional clinical studies with Xencor’s portfolio of XmAb® drug candidates, including novel bispecific antibodies and engineered cytokines. Xencor is committing to funding and supporting these studies over an initial five-year term.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200903005186/en/\n\n“MD Anderson is a leader in clinical research for both hematological and solid tumor oncology, and we are excited to enter this broad collaboration,” said Allen Yang, M.D., Ph.D., senior vice president and chief medical officer at Xencor. “This alliance partnership will enable us to expand our ongoing efforts into additional indications, generate new clinical insights, inform key decisions and accelerate development timelines across our oncology portfolio. We look forward to working closely with MD Anderson as we advance new therapies to patients in need.”\n\n\nXencor’s clinical-stage bispecific antibodies and cytokines are engineered with a heterodimer Fc domain (antibody tail), which enables their rapid design, simplified development and stable structure. Nine XmAb bispecific antibodies and one engineered cytokine are being evaluated in Phase 1 clinical studies conducted by Xencor and its partners:\n\n\n\nCD3 bispecific antibodies contain a tumor associated antigen (TAA) binding domain and a second binding domain targeted to CD3, an activating receptor on T cells, with the goal to recruit or activate T cells against tumors with the antigen target. Xencor’s CD3 bispecific candidates in Phase 1 development include vibecotamab (CD123 x CD3) for patients with acute myeloid leukemia, plamotamab (CD20 x CD3) for patients with B cell malignancies and tidutamab (SSTR2 x CD3) for patients with neuroendocrine tumors and gastrointestinal stromal tumors.\n\n\n\n\nTumor microenvironment (TME) activator bispecific antibodies promote tumor-selectiv...